Skip to main content

Table 3 Results of Meta-Analysis Evaluating the Association Between Prescriber and Patient Characteristics and Warfarin Use

From: Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis

Characteristic N Studies Pooled OR (95%CI) I2 Qp Egger's p
Advancing (dichotomous) age* 11 0.57 (0.39-0.82) 79% < 0.0001 0.40
Age per 10 year increase 4 0.78 (0.68-0.90) 70% 0.02 0.20
Alcohol or drug abuse 2 0.62 (0.40-0.96) NA 0.72 NA
Coronary artery disease 3 1.08 (0.82-1.42) 39% 0.20 NA
Congestive heart failure 8 1.36 (1.18-1.57) 84% < 0.0001 0.60
Contraindications to warfarin 3 0.81 (0.69-0.96) 0% 0.58 NA
Cerebral vascular accident 10 1.58 (1.15-2.18) 93% < 0.0001 0.84
Dementia 3 0.32 (0.14-0.75) 78% 0.01 NA
Diabetes 2 1.11 (0.97-1.26) NA 0.52 NA
Falls 4 0.60 (0.43-0.85) 83% 0.0006 0.25
Gastrointestinal bleeding 3 0.47 (0.40-0.55) 0% 0.51 NA
History of bleeding 3 0.47 (0.21-1.03) 80% 0.007 NA
Hepatic impairment 2 0.59 (0.50-0.70) NA > 0.99 NA
Hypertension 5 1.34 (0.99-1.81) 91% < 0.0001 0.48
Intracranial bleeding 3 0.39 (0.28-0.55) 2% 0.36 NA
Male gender 11 1.12 (1.04-1.21) 58% 0.008 0.17
Perceived barriers to compliance 2 0.87 (0.76-0.99) NA 0.32 NA
Renal impairment 6 0.69 (0.60-0.80) 70% 0.005 0.40
  1. N = number of studies; NA = not available/applicable; OR = odds ratio; Qp = Q statistic p-value
  2. *Advancing age analysis included any study reporting the odds of warfarin use dichotomously stratified by age. Age of stratification may have been 65, 75, or 80 years of age and was not disclosed in one study
\